mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study
CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity, and in people with HIV and hybrid immunity, CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.
Abstract
T cell correlates of COVID-19 risk are poorly defined, particularly in people with HIV (PWH). CoVPN 3008 (NCT05168813) Part A was a prospective 14,002-participant cohort study that administered one or two doses of mRNA-1273 COVID-19 vaccine, depending on baseline SARS-CoV-2 serostatus, in participants (83% PWH) in sub-Saharan Africa. Participants self-monitored for prespecified COVID-19 symptoms, defined by Centers for Disease Control and Prevention symptom criteria. Previous work showed that protection from COVID-19 was superior for hybrid versus vaccine-induced immunity, and that neutralizing antibody titers inversely associated with COVID-19 risk. In the present work, we measured T cell responses to Spike and Nucleocapsid at baseline and 4 weeks post last-vaccination (Peak) in a case-cohort study and assessed them as correlates of risk. In Hybrid Group PWH (n = 22 cases), COVID-19 risk over 6 months decreased with increasing Peak Spike BA.4/5-specific CD4 + T cell responses, from 15.8%, 4.7%, and 0% risk at 0.1%, 0.2%, and 0.3% IFN-γ and/or IL-2 response magnitude, respectively. Including baseline Spike-specific neutralizing antibody titer and Peak CD4 + T cell functionality score in the same model increased the association’s strength (overall p < 0.001). Thus, CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity. In people with HIV and hybrid immunity (prior SARS-CoV-2 infection + vaccination), CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.
The relationship between SARS-CoV-2-specific T cell responses and COVID-19 risk is incompletely understood, particularly after variant-adapted booster receipt. We assessed Spike-specific and Nucleocapsid-specific CD4+ and CD8+ T cell responses, measured by validated 27-color intracellular cytokine staining assay, as co...
Bo Zhang, You-Yi Fong, Chen-Chen Yu et al.· Nature Communications· 0 citations
Background People living with HIV (PLWHA) may experience increased vulnerability to SARS‐CoV‐2 infection and severe COVID‐19 due to immune dysregulation, comorbidities, and treatment adherence challenges. Kenya has over 1.4 million PLWHA. However, only a few have been reported with severe COVID‐19, suggesting potential...
James Kinoti Njue, L. Wekesa, Alex Maiyo et al.· AIDS Research and Treatment· 0 citations
Background Durability and breadth of SARS-CoV-2-specific T-cell responses following booster vaccination remain key to guiding next-generation vaccine design, especially in the context of waning antibodies, emerging variants, and diverse immunological backgrounds. This longitudinal study assessed IFN-γ-producing T-cell...
A. Maru, Precious Kwesi Kumi, A. Pobee et al.· Frontiers in Cellular and In...· 0 citations
Three inactivated vaccine doses were associated with higher NAb and IgG positivity overall and among three-dose recipients, NAb positivity was lower with hematologic diseases than without documented hematologic disease or solid tumors, and intervals were modestly longer with hematologic diseases.
Hai-Ying Zhang, Xin Wang, Run-Ling Zhang et al.· Frontiers in Public Health· 0 citations
Early after household exposure, binding and neutralising antibodies were similar in all participants, but differences in T-cell functional responses were evident in individuals who developed symptoms after SARS-CoV-2 infection.
Christopher Kandel, Jessica A. Breznik, Maureen Taylor et al.· The Lancet Microbe· 0 citations
Summary Background COVID-19 vaccination before primary infection is associated with decreased risk for post COVID-19 condition, but its effectiveness in populations with pre-existing immunity against SARS-CoV-2 is unknown. Our aim was to assess the COVID-19 vaccine effectiveness against post COVID-19 condition of four...
Lisa Morris, E. Bulow, Hui-Qi Li et al.· EClinicalMedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.